Aquestive Therapeutics Statistics
Share Statistics
Aquestive Therapeutics has 91.18M shares outstanding. The number of shares has increased by 1.35% in one year.
| Shares Outstanding | 91.18M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.13% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 77.61M |
| Failed to Deliver (FTD) Shares | 67.06K |
| FTD / Avg. Volume | 4.2% |
Short Selling Information
The latest short interest is 9.65M, so 10.59% of the outstanding shares have been sold short.
| Short Interest | 9.65M |
| Short % of Shares Out | 10.59% |
| Short % of Float | 12.44% |
| Short Ratio (days to cover) | 6.35 |
Valuation Ratios
The PE ratio is -15.72 and the forward PE ratio is -8.32.
| PE Ratio | -15.72 |
| Forward PE | -8.32 |
| PS Ratio | 2.45 |
| Forward PS | 3.5 |
| PB Ratio | -1.16 |
| P/FCF Ratio | -16.78 |
| PEG Ratio | n/a |
Enterprise Valuation
Aquestive Therapeutics Inc. has an Enterprise Value (EV) of 198.69M.
| EV / Earnings | -25.25 |
| EV / Sales | 3.93 |
| EV / EBITDA | 168.09 |
| EV / EBIT | -13.16 |
| EV / FCF | -26.94 |
Financial Position
The company has a current ratio of 2.24, with a Debt / Equity ratio of -0.31.
| Current Ratio | 2.24 |
| Quick Ratio | 1.87 |
| Debt / Equity | -0.31 |
| Total Debt / Capitalization | -45.54 |
| Cash Flow / Debt | -0.19 |
| Interest Coverage | -2.02 |
Financial Efficiency
Return on equity (ROE) is 0.07% and return on capital (ROIC) is 21.3%.
| Return on Equity (ROE) | 0.07% |
| Return on Assets (ROA) | -0.14% |
| Return on Capital (ROIC) | 21.3% |
| Revenue Per Employee | 374.69K |
| Profits Per Employee | -58.30K |
| Employee Count | 135 |
| Asset Turnover | 0.88 |
| Inventory Turnover | 3.08 |
Taxes
| Income Tax | 245.00K |
| Effective Tax Rate | -0.03 |
Stock Price Statistics
The stock price has increased by 14.29% in the last 52 weeks. The beta is 2.82, so Aquestive Therapeutics 's price volatility has been higher than the market average.
| Beta | 2.82 |
| 52-Week Price Change | 14.29% |
| 50-Day Moving Average | 4.2 |
| 200-Day Moving Average | 3.93 |
| Relative Strength Index (RSI) | 29.53 |
| Average Volume (20 Days) | 1.60M |
Income Statement
In the last 12 months, Aquestive Therapeutics had revenue of 50.58M and earned -7.87M in profits. Earnings per share was -0.13.
| Revenue | 50.58M |
| Gross Profit | 29.75M |
| Operating Income | -15.10M |
| Net Income | -7.87M |
| EBITDA | 1.18M |
| EBIT | -15.10M |
| Earnings Per Share (EPS) | -0.13 |
Balance Sheet
The company has 23.87M in cash and 33.32M in debt, giving a net cash position of -9.45M.
| Cash & Cash Equivalents | 23.87M |
| Total Debt | 33.32M |
| Net Cash | -9.45M |
| Retained Earnings | -319.08M |
| Total Assets | 109.96M |
| Working Capital | 81.42M |
Cash Flow
In the last 12 months, operating cash flow was -6.38M and capital expenditures -995.00K, giving a free cash flow of -7.38M.
| Operating Cash Flow | -6.38M |
| Capital Expenditures | -995.00K |
| Free Cash Flow | -7.38M |
| FCF Per Share | -0.12 |
Margins
Gross margin is 58.82%, with operating and profit margins of -29.86% and -15.56%.
| Gross Margin | 58.82% |
| Operating Margin | -29.86% |
| Pretax Margin | -15.07% |
| Profit Margin | -15.56% |
| EBITDA Margin | 2.34% |
| EBIT Margin | -29.86% |
| FCF Margin | -14.58% |
Dividends & Yields
AQST does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -4.28% |
| FCF Yield | -2.66% |
Analyst Forecast
The average price target for AQST is $9, which is 196.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $9 |
| Price Target Difference | 196.1% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Scores
| Altman Z-Score | -2.34 |
| Piotroski F-Score | 4 |